563 related articles for article (PubMed ID: 1906407)
1. Norplant implants: the mechanism of contraceptive action.
Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
[TBL] [Abstract][Full Text] [Related]
2. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
3. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
4. Absence of chorionic gonadotropin in sera of women who use intrauterine devices.
Segal SJ; Alvarez-Sanchez F; Adejuwon CA; Brache de Mejia V; Leon P; Faundes A
Fertil Steril; 1985 Aug; 44(2):214-8. PubMed ID: 4018277
[TBL] [Abstract][Full Text] [Related]
5. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
6. Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and follicular development.
Brache V; Alvarez F; Faundes A; Cochon L; Thevenin F
Fertil Steril; 1996 Jun; 65(6):1110-4. PubMed ID: 8641481
[TBL] [Abstract][Full Text] [Related]
7. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
8. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
[TBL] [Abstract][Full Text] [Related]
9. Return of fertility following discontinuation of Norplant-II subdermal implants. ICMR Task Force on Hormonal Contraception.
Buckshee K; Chatterjee P; Dhall GI; Hazra MN; Kodkany BS; Lalitha K; Logambal A; Manchanda P; Nanda UK; RaiChoudhury G
Contraception; 1995 Apr; 51(4):237-42. PubMed ID: 7796589
[TBL] [Abstract][Full Text] [Related]
10. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
[TBL] [Abstract][Full Text] [Related]
11. The secretion of human chorionic gonadotropin-like substance in women employing contraceptive measures.
Huang SC; Chen HC; Chen RJ; Hsieh CY; Wei PY; Ouyang PC
J Clin Endocrinol Metab; 1984 Apr; 58(4):646-53. PubMed ID: 6699130
[TBL] [Abstract][Full Text] [Related]
12. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
Alvarez F; Brache V; Tejada AS; Faúndes A
Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
[TBL] [Abstract][Full Text] [Related]
13. NORPLANT contraceptive implants advancing.
Segal SJ
Netw Res Triangle Park N C; 1984; 5(3):1-3. PubMed ID: 12279797
[TBL] [Abstract][Full Text] [Related]
14. Use of levonorgestrel implants versus oral contraceptives in adolescence: a case-control study.
Berenson AB; Wiemann CM
Am J Obstet Gynecol; 1995 Apr; 172(4 Pt 1):1128-35; discussion 1135-7. PubMed ID: 7726249
[TBL] [Abstract][Full Text] [Related]
15. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
[TBL] [Abstract][Full Text] [Related]
16. Levonorgestrel subdermal implants (Norplant) for long-term contraception.
Sharts-Engel NC
MCN Am J Matern Child Nurs; 1991; 16(4):232. PubMed ID: 1943533
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy-specific beta 1-glycoprotein and chorionic gonadotropin-like immunoreactivity during the latter half of the cycle in women using intrauterine contraception.
Seppälä M; Rutanen EM; Jalanko H; Lehtovirta P; Stenman UH; Engvall E
J Clin Endocrinol Metab; 1978 Dec; 47(6):1216-9. PubMed ID: 318094
[TBL] [Abstract][Full Text] [Related]
18. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study.
Sivin I; Campodonico I; Kiriwat O; Holma P; Diaz S; Wan L; Biswas A; Viegas O; el din Abdalla K; Anant MP; Pavez M; Stern J
Hum Reprod; 1998 Dec; 13(12):3371-8. PubMed ID: 9886517
[TBL] [Abstract][Full Text] [Related]
19. New concepts in contraception: Norplant subdermal implant.
Lynn MM; Holdcroft C
Nurse Pract; 1992 Mar; 17(3):85-9. PubMed ID: 1565306
[TBL] [Abstract][Full Text] [Related]
20. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
Sivin I; Lähteenmäki P; Mishell DR; Alvarez F; Diaz S; Ranta S; Grozinger C; Lacarra M; Brache V; Pavez M; Nash H; Stern J
Contraception; 1997 Nov; 56(5):317-21. PubMed ID: 9437561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
